'''Metazocine''' is an [[opioid]] [[analgesic]] related to [[pentazocine]]. While metazocine has significant analgesic effects,<ref>Hori M, Ban M, Imai E, Iwata N, Suzuki Y, Baba Y, Morita T, Fujimura H, Nozaki M, Niwa M. Novel nonnarcotic analgesics with an improved therapeutic ratio. Structure-activity relationships of 8-(methylthio)- and 8-(acylthio)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines. ''Journal of Medicinal Chemistry''. 1985 Nov;28(11):1656-61.</ref> mediated through a mixed [[agonistâ€“antagonist]] action<ref>Berzetei-Gurske I, Loew GH. The novel antagonist profile of (-)metazocine. ''Progress in Clinical and Biological Research''. 1990;328:33-6.</ref> at the [[mu opioid receptor]],<ref>Gharagozlou P, Demirci H, David Clark J, Lameh J. Activity of opioid ligands in cells expressing cloned mu opioid receptors. ''BMC Pharmacology''. 2003 Jan 4;3:1.</ref> its clinical use is limited by [[dysphoric]] and [[hallucinogenic]] effects which are most likely caused by activity at [[kappa opioid receptor]]s (where it is a high-efficacy agonist)<ref>Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J. Pharmacological profiles of opioid ligands at kappa opioid receptors. ''BMC Pharmacology''. 2006 Jan 25;6:3.</ref> and/or [[sigma receptor]]s.<ref>Shannon HE. Pharmacological analysis of the phencyclidine-like discriminative stimulus properties of narcotic derivatives in rats. ''Journal of Pharmacology and Experimental Therapeutics''. 1982 Jul;222(1):146-51.</ref><ref>Slifer BL, Balster RL, May EL. Reinforcing and phencyclidine-like stimulus properties of enantiomers of metazocine. ''Pharmacology, Biochemistry and Behaviour''. 1986 Oct;25(4):785-9.</ref> 
